Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Bexagliflozin

tablets containing 20 mg bexagliflozin

DRUG

Placebo

tablets matching the appearance of bexagliflozin tablets

Trial Locations (23)

28467

Research Site, Calabash

28557

Research Site, Morehead City

29582

Research Site, North Myrtle Beach

32127

Research Site, Port Orange

32806

Research Site, Orlando

33012

Research Site, Hialeah

33016

Research Site, Miami Lakes

33316

Research Site, Fort Lauderdale

44262

Research Site, Munroe Falls

75115

Research Site, DeSoto

76164

Research Site, Fort Worth

90057

Research Site, Los Angeles

90255

Research Site, Huntington Park

91303

Research Site, Canoga Park

91710

Research Site, Chino

92103

Research Site, San Diego

97239

Research Site, Portland

08611

Research Site, Trenton

V6J 1S3

Research Site, Vancouver

L3Y 5G8

Research Site, Newmarket

M9V 4B4

Research Site 2, Toronto

M9W 4L6

Research Site 1, Toronto

H9R 4S3

Research Site, Pointe-Claire

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theracos

INDUSTRY

NCT02715258 - Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter